地理缩:病理生理学和当前的治疗策略
Kalpana Rajanala1, Farokh Dotiwala1, Arun Upadhyay1
1Research and Development, Ocugen Inc., Malvern, PA, United States.
Frontiers in ophthalmology
|July 10, 2024
概括
地理缩 (GA) 是一种与年龄相关的黄斑变性 (AMD) 的高级形式,导致不可逆转的视力丧失. 虽然新的治疗方法减缓了进展,但它们无法治愈GA,这凸显了对更好的治疗方法的需求.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 与年龄相关的斑点退化 (AMD)
背景情况:
- 地理缩 (GA) 是AMD的一个晚期阶段,其特点是由于光受体和视网膜色素上皮质 (RPE) 细胞死亡而逐渐失去视力.
- 危险因素包括老年,家族病史,吸烟和遗传变异.
- 诊断依赖于全面的眼科检查和像OCT和 fundus摄影这样的成像.
研究的目的:
- 审查地理缩 (GA) 的病理生理学.
- 讨论目前批准的GA治疗方法,包括它们的局限性.
- 探索潜在的未来治疗策略对GA.
主要方法:
- 关于地理缩 (GA) 病理生理学,诊断和治疗的文献综述.
- 对FDA最近批准的GA疗法 (Syfovre和Izervay) 的分析.
- 讨论正在进行的临床试验和GA治疗的未满足需求.
主要成果:
- 像Syfovre和Izervay这样的FDA批准的新疗法在减缓GA进展方面显示出潜力.
- 目前的疗法提供了好处,但没有提供治愈,并且在有效性和安全性方面存在局限性.
- 对于具有提高疗效,安全性和患者遵从性的新疗法存在重大需求.
结论:
- 地理缩 (GA) 代表了与年龄相关的黄斑变性 (AMD) 管理的重大挑战.
- 虽然最近的治疗进步提供了希望,但它们强调了对更有效的治疗方法的迫切需要.
- 未来的研究应该专注于开发具有增强疗效,更好的安全性和改善患者坚持治疗的疗法.
相关概念视频
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
01:15Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461